Ubs Group Ag Eliem Therapeutics, Inc. Transaction History
Ubs Group Ag
- $397 Billion
- Q1 2024
A detailed history of Ubs Group Ag transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 5,925 shares of ELYM stock, worth $45,681. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,925Holding current value
$45,681% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding ELYM
# of Institutions
21Shares Held
3.7MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN2.19MShares$16.9 Million4.02% of portfolio
-
Driehaus Capital Management LLC Chicago, IL812KShares$6.26 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA310KShares$2.39 Million0.0% of portfolio
-
Atom Investors LP Austin, TX78.3KShares$603,5070.03% of portfolio
-
Geode Capital Management, LLC Boston, MA66.6KShares$513,6860.0% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $205M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...